Galectin Therapeutics Inc.

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Bank Name Galectin Therapeutics Inc.
Stock Exchange NASDAQ
Symbol GALT
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman
CEO Dr. Peter G. Traber
Employees 7
Website www.galectintherapeutics.com
Registered Year 2000

UpdateContent
UpdateContent
UpdateContent